ImmuneOnco is a tumor immunotherapy product developer engaged in the development and research of tumor immunotherapy products.
ImmuneOnco Biopharma, founded in June of 2015 in Zhangjiang High-Tech Park of Shanghai, China, is an early stage biopharmaceutical company dedicated to the development and commercialization of novel cancer immunotherapy products designed to reverse cancer cell-induced immune inhibition and to actively eradicate cancer cells.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Dec 31, 2021 | Series Unknown | $100M | 2 | — | — | Detail |
Oct 12, 2020 | Series B | $25M | 2 | Lilly Asia Ventures | — | Detail |
Apr 11, 2018 | Series A | $15.80M | 2 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Milestone | — | Series Unknown |
Lilly Asia Ventures | — | Series Unknown |
Chongde Hongxin | — | Series A |